2026 Is the Year of Obesity Pills. Here's How They Could Reshape the GLP-1 Market

Obesity pills: How they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter.

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.

2026 is the year of obesity pills from Novo Nordisk, Eli Lilly

The post 2026 is the year of obesity pills from Novo Nordisk, Eli Lilly appeared on BitcoinEthereumNews.com. The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. A GLP-1 pill fro…